|
Peginterferon alfa-2b
resources
|
|
|
|
|
|
DRUG INFO
Peginterferon alfa-2b
Drug Name:
Peginterferon alfa-2b
Indication: For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Drug Category: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20)
Brand Names/Synonyms: Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; PEG-Intron
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: PEGylated human interferon alpha 2b
Chemical Formula: C860H1353N229O255S9
Half Life: 22-60 hrs
Drug Type: Approved Drug
# Accession No: BIOD00048
CAS Registry Number: 99210-65-8
|
|
|
|
|
|
Peginterferon alfa-2b News
(When available)
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... Jan 12, 2006
PR Newswire (press release), ENDURE Study to Assess Low-Dose PEG-INTRON Monotherapy in Helping to Prevent Hepatitis C Disease Progression in Coinfected Patients AMSTERDAM, Netherlands, Jan ...
Schering-Plough Initiates PEG-INTRON Maintenance Study in Patients ... Jan 13, 2006
PharmaLive.com (press release), Schering-Plough announced today that it is initiating a large multinational clinical trial to evaluate the use of low-dose PEG-INTRON(R) (peginterferon alfa-2b ...
Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in ... Dec 22, 2005
PR Newswire (press release), Plough KK, the company's country operations in Japan, has received marketing approval for a new, additional indication for PEG-INTRON(R) (peginterferon alfa-2b ...
Schering-Plough Announces PEG-Intron and Rebetol Approved in Japan ... Dec 22, 2005
DG News Plough KK, the company's country operations in Japan, has received marketing approval for a new, additional indication for PEG-Intron® (peginterferon alfa-2b ...
International Approvals: Erbitux, Peg-Intron, Rebetol Dec 27, 2005
Medscape (subscription) Ministry of Health, Labor, and Welfare approved an expanded indication for peginterferon alfa-2b in combination with ribavirin (Peg-Intron injection and ...
Schering-Plough Initiates PEGINTRON(R) Maintenance Study in ... Jan 12, 2006
PR Newswire UK (press release), 5. EPIC3 (Evaluation of PEG-INTRON in Control of Hepatitis C Cirrhosis), a large multicenter, multi-part treatment and maintenance therapy clinical study ...
Vertex Hepatitis C Treatment Fast, Potent in Combination Study Jan 9, 2006
Bloomberg ...pill, ribavirin. The goal would be to use VX-950 in combination with Pegasys or Peg-Intron for most effective results. ``Our best ...
(PRN) - Following Is a Test Release ... [+] Jan 13, 2006
Bolsamania.com, Yogurts ... [+. PRN) - Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV ... [+. ...
Subject: Jim Cramer's Action Alerts PLUS Weekly Roundup Jan 13, 2006
TheStreet.com (subscription), Schering-Plough (SGP:NYSE, $20.20, 4,000 shares, 2.00%): Announced a new hepatitis C study Friday, using low doses of its Peg-Intron drug. ...
Human Genome Sciences Reports on Progress Toward Commercialization ... Jan 10, 2006
PR Newswire (press release), This compares to a reported mean elimination half- life of 80 hours (50-140 hours) for Pegasys and 40 hours (22-60 hours) for PEG-Intron.(25-26) These data are ...
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 9, 2006
dBusinessNews Newark (press release), In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals ...
Vertex Hepatitis C Treatment Show Promise in Study (Update2) Jan 9, 2006
Bloomberg ...the product to be used together with standard therapies such as Roche Holding AG's injection drug Pegasys or Schering-Plough Corp.'s injected Peg-Intron. ...
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ... Jan 4, 2006
PR Newswire (press release), ...refractory anaplastic astrocytoma, (3) Clarinex(R)/Claritin(R) (anti-histamine), for the treatment of seasonal allergic rhinitis, (4) peg-intron(R) (pegilated ...
Schering-Plough Gets Japan OK for Drug Dec 22, 2005
Schaeffers Research, The company said the Japanese Ministry of Health, Labor and Welfare approved Schering-Plough KK's application to market Peg-Intron injectable interferon with ...
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 6, 2006
Finanzen.net, In addition, Enzon alsoreceives royalties on sales of PEG-INTRON(R), marketed bySchering-Plough Corporation, and MACUGEN(R), marketed by OSIPharmaceuticals and ...
(PRN) - Nobility Homes, Inc. Announces Record Sales and Earnings ... Dec 22, 2005
Bolsamania.com, ...[+]. (PRN) - Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in Japan for Expanded Use in Treating Chronic Hepatitis C ... [+. ...
|
|
|
